Results 51 to 60 of about 284,324 (192)

Adenovirus-Mediated Sensitization to the Cytotoxic Drugs Docetaxel and Mitoxantrone Is Dependent on Regulatory Domains in the E1ACR1 Gene-Region [PDF]

, 2012
Oncolytic adenoviruses have shown promising efficacy in clinical trials targeting prostate cancers that frequently develop resistance to all current therapies.
Halldén Gunnel, Miranda, Enrique, Maya Pineda, Hector, Oeberg, D, Cherubini Gioia, Zita Garate (130698), Maya Pineda Hector, Gunnel Halldén, Lemoine Nick R., Öberg, Daniel,, Nick R. Lemoine (130704), Lemoine, NR, Maya Pineda, H, Gunnel Halldén (130708), Nick R Lemoine, Gioia Cherubini, Daniel Öberg (130690), Halldén, G, Miranda Enrique, Garate Zita, Hector Maya Pineda, Öberg Daniel, Garate, Zita, Garate, Z, Zita Garate, Enrique Miranda (130684), Pineda, HM, Daniel Öberg, Halldén, Gunnel, Enrique Miranda, Öberg, D, Lemoine, Nick R, Hector Maya Pineda (130688), Cherubini, Gioia, Gioia Cherubini (130694), Miranda, E, Cherubini, G   +36 more
core   +1 more source

Current strategies in engaging oncolytic viruses with antitumor immunity

Molecular Therapy: Oncolytics, 2021
Oncolytic virotherapy has produced promising yet limited results in preclinical and clinical studies. Besides direct oncolytic activity, a significant therapeutic mechanism of oncolytic virotherapy is the induction of tumor-specific immunity ...
Drew Ashton Boagni, Divya Ravirala, Shaun Xiaoliu Zhang   +2 more
doaj   +1 more source

Status and future of recombinant adeno‐associated virus vector manufacturing

Biotechnology Progress, EarlyView.
Abstract Sixty years of adeno‐associated virus (AAV) research illustrates a trajectory marked by basic science exploration, iterative innovation, persistent challenges, a number of clinical setbacks, as well as commercial therapeutic triumphs. This continual evolution has led to recombinant AAV (rAAV) becoming a cornerstone of modern gene therapy ...
Frank Agbogbo, David Dismuke
wiley   +1 more source

The combination therapy of oncolytic virotherapy

Frontiers in Pharmacology
Introduction: Compared to other cancer immunotherapies, oncolytic viruses possess several advantages, including high killing efficiency, excellent targeting capabilities, minimal adverse reactions, and multiple pathways for tumor destruction.
Yue Wang, Mengying Zhu, Mengying Zhu, Huanyu Chi, Huanyu Chi, Yang Liu, Guilin Yu   +6 more
doaj   +1 more source

Ovarian Cancer: Epidemiology, Disease Mechanisms, New Diagnosis and Treatment Strategies, and Research Directions

iNew Medicine, EarlyView.
ABSTRACT Ovarian cancer (OC) continues to be the deadliest gynecological malignancy and a significant cause of cancer‐related mortality among women worldwide. Standard treatment strategies typically entail platinum‐based chemotherapy in conjunction with cytoreductive surgery.
Zunera Khalid, Weirong Fan, Farah Nazir, Yixiang Xing, Tengchuan Jin   +4 more
wiley   +1 more source

Regulation of adenovirus replication by miR-199 confers a selective oncolytic activity in hepatocellular carcinoma [PDF]

, 2012
Oncolytic virotherapy represents a growing field of experimental cancer therapy. For safe and effective virotherapy, restricted tissue expression and replication of the virus is desirable.
Khalid Elamin Elhag, Baha Eldin
core  

The multifunctional NS1 protein of influenza A viruses [PDF]

, 2008
The non-structural (NS1) protein of influenza A viruses is a non-essential virulence factor that has multiple accessory functions during viral infection.
Hale, Benjamin Geoffrey, Hale, B.G., Ortin, J., Jackson, D., Randall, Richard Edward, Randall, R.E., Jackson, David, Ortin, J   +7 more
core   +2 more sources

Syncytia Formation in Oncolytic Virotherapy

Molecular Therapy: Oncolytics, 2019
Oncolytic virotherapy uses replication-competent virus as a means of treating cancer. Whereas this field has shown great promise as a viable treatment method, the limited spread of these viruses throughout the tumor microenvironment remains a major ...
Chase Burton, Eric Bartee
doaj   +1 more source

A Multiple‐Model‐Informed Drug‐Development Approach for Optimal Regimen Selection of an Oncolytic Virus in Combination With Pembrolizumab

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 572-582, March 2025.
ABSTRACT The antitumor efficacy of an intratumoral injection of a genetically engineered oncolytic vaccinia virus carrying human IL‐7 and murine IL‐12 genes (hIL‐7/mIL‐12‐VV) was demonstrated in CT26.WT‐bearing mice. In the CT26.WT‐bearing mouse model, the efficacy of the combination of hIL‐7/mIL‐12‐VV plus the anti‐programmed cell death protein (PD)‐1
Akihiro Yamada, Mary P. Choules, Frances A. Brightman, Shigeru Takeshita, Shinsuke Nakao, Nobuaki Amino, Takeshi Nakayama, Masato Takeuchi, Kanji Komatsu, Fernando Ortega, Hitesh Mistry, David Orrell, Christophe Chassagnole, Peter L. Bonate   +13 more
wiley   +1 more source

Engineered oncolytic virus coated with anti-PD-1 and alendronate for ameliorating intratumoral T cell hypofunction

Experimental Hematology & Oncology
Background Glioblastoma is a highly aggressive and devastating primary brain tumor that is resistant to conventional therapies. Oncolytic viruses represent a promising therapeutic approach for glioblastoma by selectively lysing tumor cells and eliciting ...
Yufu Zhu, Xuefeng Zhang, Jiaqi Jin, Xiaoqian Wang, Yang Liu, Jian Gao, Diancheng Hang, Lin Fang, Hengzhu Zhang, Hongmei Liu   +9 more
doaj   +1 more source